CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer
therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer
cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase
1 study. The objective of the phase 2 study is to further investigate the efficacy of
CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.